CDKN2A and pancreatic neoplasm: Pathogenic variants in CDKN2A increase the risk for pancreatic cancer (~ 5% to 24% lifetime risk), and individuals with pathogenic variants in CDKN2A tend to have an earlier onset of cancer [65, 66].